CDK
Los inhibidores de las quinasas dependientes de ciclina (CDK) son compuestos que bloquean la actividad de las CDK, un grupo de quinasas de proteínas que regulan el ciclo celular, la transcripción y otros procesos celulares. Las CDK se activan al unirse a las ciclinas, y su actividad es crucial para la progresión de las células a través de las diferentes fases del ciclo celular. Inhibir las CDK puede detener la división celular, provocando la detención del ciclo celular y la apoptosis, especialmente en células cancerosas donde las CDK a menudo están desreguladas. Los inhibidores de CDK se utilizan ampliamente en la investigación del cáncer y tienen un potencial terapéutico en el tratamiento de varios tipos de cáncer. En CymitQuimica, ofrecemos una selección completa de inhibidores de CDK de alta calidad para apoyar su investigación en el control del ciclo celular, el cáncer y el desarrollo terapéutico.
Se han encontrado 546 productos de "CDK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
dCeMM2
CAS:dCeMM2 degrades glue by promoting CDK12-cyclin K ubiquitination and degradation via CRL4B ligase interaction.Fórmula:C16H11ClN6OSPureza:99.68%Forma y color:SolidPeso molecular:370.82Ref: TM-T61477
1mg34,00€5mg74,00€10mg113,00€25mg236,00€50mg404,00€100mg600,00€500mg1.279,00€1mL*10mM (DMSO)104,00€hSMG-1 inhibitor 11e
CAS:hSMG-1 inhibitor 11e is an effective and selective inhibitor of hSMG-1 (IC50 <0.05 nM) and can be used in studies about cancer treatment.Fórmula:C26H27N7O3SPureza:99.89%Forma y color:SolidPeso molecular:517.6CDK8-IN-1
CAS:CDK8-IN-1 is a selective CDK8 inhibitor (IC50: 3 nM).Fórmula:C11H8F3N3OPureza:98.48%Forma y color:SolidPeso molecular:255.2Ref: TM-T10740
1mg87,00€5mg216,00€10mg311,00€25mg525,00€50mg707,00€100mg944,00€1mL*10mM (DMSO)240,00€DIF-3
CAS:DIF-3 activates GSK-3β, degrades cyclin D1/c-Myc, and inhibits Wnt/β-catenin in DLD-1 cells, curbing HeLa cell proliferation.Fórmula:C13H17ClO4Pureza:99.57%Forma y color:SolidPeso molecular:272.72Ref: TM-T60485
1mg96,00€5mg222,00€10mg333,00€25mg557,00€50mg795,00€100mg1.071,00€500mg2.187,00€1mL*10mM (DMSO)205,00€SRX3177
CAS:SRX3177 is a novel and potent inhibitor of BRD4, PI3K and CDK.SRX3177 has potential anticancer activity.Fórmula:C31H32N6O4SPureza:99.16%Forma y color:SolidPeso molecular:584.69Ref: TM-T69742
1mg70,00€5mg150,00€10mg215,00€25mg358,00€50mg517,00€100mg707,00€1mL*10mM (DMSO)178,00€9-Isopropylolomoucine
CAS:9-Isopropylolomoucine (N9-Isopropylolomoucine), a cell cycle protein-dependent kinase inhibitor, is a thiopurine.Fórmula:C17H22N6OPureza:99.82%Forma y color:SolidPeso molecular:326.4Ref: TM-T23589
1mg315,00€5mg745,00€10mg1.018,00€25mg1.431,00€50mg1.783,00€100mg2.250,00€500mg4.410,00€1mL*10mM (DMSO)607,00€(S)-PF-06873600
CAS:(S)-PF-06873600 is the S enantiomer of PF-06873600 which is an inhibitor of CDK.Fórmula:C20H27F2N5O4SPureza:98.59%Forma y color:SolidPeso molecular:471.52CLK-IN-T3
CAS:CLK-IN-T3 is an inhibitor of CLK1, CLK2, and CLK3 with IC50s of 0.67, 15, and 110 nM. CLK-IN-T3 exhibits anti-cancer activity.Fórmula:C28H30N6O2Pureza:99.61%Forma y color:SolidPeso molecular:482.58Ref: TM-T14980
1mg47,00€2mg62,00€5mg92,00€10mg160,00€25mg289,00€50mg505,00€100mg787,00€200mg1.063,00€PS423
CAS:PS423 is a substrate-selective protein kinase PDK1 inhibitor that acts by binding to the PIF-pocket allosteric docking site.Fórmula:C25H23F3O9Pureza:98.81% - 99.26%Forma y color:SolidPeso molecular:524.44EHT 1610
CAS:EHT 1610 (EHT 5372) is a potent inhibitor of DYRK, with an IC50 of 0.36 nM and 0.59 nM for DYRK1A and DYRK1B, respectively.Fórmula:C18H14FN5O2SPureza:98.43%Forma y color:SolidPeso molecular:383.4BML-259
CAS:BML-259 inhibits CDK5/CDK2 (IC50: 64/98 nM) for cancer and neurodegeneration research.Fórmula:C14H16N2OSPureza:99.84%Forma y color:SolidPeso molecular:260.35Ref: TM-T36964
5mg48,00€10mg80,00€25mg160,00€50mg264,00€100mg462,00€500mg982,00€1mL*10mM (DMSO)50,00€CDK9-IN-10
CAS:CDK9-IN-10 is a potent CDK9 inhibitor and the ligand for the PROTAC CDK9 degrader-2.Fórmula:C22H16O5Pureza:99.8%Forma y color:SolidPeso molecular:360.36Ryuvidine
CAS:Ryuvidine is a dual inhibitor of KDM5A and SETD8, an inducer of the DNA damage response, and can be used to study breast cancer and erythroderma.Fórmula:C15H12N2O2SPureza:98.6%Forma y color:SolidPeso molecular:284.33Palbociclib orotate
CAS:Palbociclib (PD 0332991) orotate, an orally active selective inhibitor of CDK4 and CDK6, exhibits IC50 values of 11 and 16 nM, respectively.Fórmula:C29H33N9O6Pureza:98%Forma y color:SolidPeso molecular:603.63CDK4-IN-2
CAS:CDK4-IN-2 (A17) is a potent inhibitor of CDK4, exhibiting K i and IC 50 values of less than 10 nM and is utilized in cancer research [1].Fórmula:C22H26F2N6O4SPureza:98%Forma y color:SolidPeso molecular:508.54CDK-IN-11
CAS:CDK-IN-11, a heterocyclic compound, promotes cardiomyocyte maturation [1].Fórmula:C25H21BrN4O2Forma y color:SolidPeso molecular:489.36EHT 5372
CAS:EHT 5372 inhibits DYRK kinases; IC50: 0.22-221 nM for DYRK1A/B, DYRK2/3, CLK1/2/4, GSK-3α/β.Fórmula:C17H11Cl2N5OSForma y color:SolidPeso molecular:404.275-Iodo-indirubin-3'-monoxime
CAS:5-Iodo-indirubin-3'-monoxime is a potent GSK-3β, CDK5/P25 and CDK1/cyclin B inhibitor, competing with ATP for binding to the catalytic site of the kinase (IC50sFórmula:C16H10IN3O2Forma y color:SolidPeso molecular:403.17Leucettinib-92
CAS:Leucettinib-92 is a multi-kinase inhibitor of DYRK and CLK families with differential nanomolar activity, supporting studies of kinase signaling regulation.Fórmula:C21H22N4OSPureza:98%Forma y color:SolidPeso molecular:378.49CDK9-IN-8
CAS:CDK9-IN-8 is a highly potent and selective CDK9 inhibitor (IC50: 12 nM).Fórmula:C31H32FN7O3Pureza:99.54%Forma y color:SolidPeso molecular:569.63Voruciclib hydrochloride
CAS:Voruciclib hydrochloride is an orally active and selective inhibitor of CDK (Ki: 0.626 nM-9.1 nM).Fórmula:C22H20Cl2F3NO5Pureza:98%Forma y color:SolidPeso molecular:506.3Bisindolylmaleimide X hydrochloride
CAS:Bisindolylmaleimide X hydrochloride (BIM-X hydrochloride) is a potent and selective PKC inhibitor. It is also a potent CDK2 antagonist (IC50: 200 nM).Fórmula:C26H25ClN4O2Pureza:99.23%Forma y color:SolidPeso molecular:460.96Senexin C
CAS:Senexin C is a CDK8/19 inhibitor with anticancer activity.Senexin C inhibits the growth of MV4-11 leukemia cells.Fórmula:C28H27N5OPureza:98.06%Forma y color:SolidPeso molecular:449.55Cdk4 Inhibitor
CAS:PD 0332991, an unsymmetrical indolocarbazole compound, is cell-permeable and exhibits antiproliferative effects by functioning as a potent, selective, reversible, and ATP-competitive inhibitor of Cdk4/D1 (IC 50 = 76 nM). Although it can inhibit other Cdks, such as Cdk2/E and Cdk1/B, effectiveness requires higher concentrations (IC 50 = 520 nM and 2.1 µM, respectively) and demonstrates minimal activity against CaMKII, PKA, or GSK-3β (IC 50 ≥ 12.4 µM). PD 0332991 efficiently inhibits tumor cell growth in HCT-116 and NCI-H460 cell lines with an IC 50 < 3.0 µM, primarily through blocking Rb phosphorylation and inducing G1 cell cycle arrest.Fórmula:C20H10BrN3O2Forma y color:SolidPeso molecular:404.2CDK9-IN-9
CAS:CDK9-IN-9 is a potent and selective CDK9 inhibitor (IC50: 1.8 nM) with anti-cancer activity. It inhibits CDK2 (IC50: 155 nM).Fórmula:C22H23F2N5O2SPureza:98%Forma y color:SolidPeso molecular:459.51Lerociclib
CAS:Lerociclib (G1T38) is a CDK4/6 inhibitor with anticancer and antitumor activities, inhibiting CDK4/CyclinD1 and CDK6/CyclinD3.Fórmula:C26H34N8OPureza:99%Forma y color:SolidPeso molecular:474.6(S)-Cdc7-IN-18
CAS:'(S)-Cdc7-IN-18 from patent WO2020239107A1 inhibits CDC7, curbing MCM2 and tumor growth.'Fórmula:C19H21N5OSForma y color:SolidPeso molecular:367.47CDK4/6-IN-17
CAS:CDK4/6-IN-17 (compound 12) is an orally bioavailable inhibitor of CDK4/6, demonstrating potent activity with IC50 values between 10-100 nM in BE(2) cells.Fórmula:C27H28F4N8Pureza:98%Forma y color:SolidPeso molecular:540.56CDK8-IN-3
CAS:CDK8-IN-3 is an inhibitor of CDK8.Fórmula:C22H23N5O2Pureza:98%Forma y color:SolidPeso molecular:389.45CDK/HDAC-IN-3
CAS:CDK/HDAC-IN-3 is an orally active dual inhibitor of HDACs and CDKs, offering potent and selective inhibition of CDK9, CDK12, CDK13, HDAC1, HDAC2, and HDAC3,Fórmula:C24H18Cl2N6O3Pureza:98%Forma y color:SolidPeso molecular:509.34Xylocydine
CAS:Xylocydine is a novel Cdk inhibitor that induces apoptosis in HCC, suppresses tumor growth, and is non-toxic to other tissues.Fórmula:C12H14BrN5O5Forma y color:SolidPeso molecular:388.17Cdc7-IN-12
CAS:Cdc7-IN-12, a sub-1 nM CDC7 inhibitor, may aid cancer research; hinders COLO205 cell growth (IC50: 100-1000 nM).Fórmula:C16H14N2O2SForma y color:SolidPeso molecular:298.36QR-6401
CAS:QR-6401, a selective macrocyclic CDK2 inhibitor, is orally active with IC50 values of 0.37 nM for CDK2/E1, 10 nM for CDK9/T1, 22 nM for CDK1/A2, 34 nM for CDK6/Fórmula:C19H23N5O3Pureza:98%Forma y color:SolidPeso molecular:369.42Senexin A hydrochloride
CAS:Senexin A hydrochloride functions as a selective inhibitor of CDK8/19, with an IC 50 of 280 nM for CDK8, and specifically inhibits p21-induced transcription without affecting other biological effects of p21. Additionally, it suppresses CMV-GFP induction and the stimulatory activity of the consensus NF-κB-dependent promoters [1] [2].Fórmula:C17H15ClN4Forma y color:SolidPeso molecular:310.78Nε-(1-Carboxyethyl)-L-lysine
CAS:Nε-(1-Carboxyethyl)-L-lysine (CEL) is an advanced glycation end-product (AGE). Exposure to CEL reduces glutamate uptake and S100B secretion in the hippocampus.Fórmula:C9H18N2O4Forma y color:SolidPeso molecular:218.25Tacaciclib
CAS:Tacaciclib is a cyclin-dependent kinase (CDK) inhibitor with observed antineoplastic activity [1].Fórmula:C30H36N6O3Pureza:98%Forma y color:SolidPeso molecular:528.65CDK4/6-IN-15
CAS:CDK4/6-IN-15: Oral, selective CDK4/6 inhibitor, halts cancer cell growth, G1 arrest, suppresses Rb phosphorylation.Fórmula:C21H27FN8SForma y color:SolidPeso molecular:442.56LDC3140
CAS:LDC3140 is a potent inhibitor of Cyclin-dependent kinase 7 (CDK7).Fórmula:C23H33N7OPureza:98%Forma y color:SolidPeso molecular:423.55PF-6808472
CAS:PF-6808472 is a cell-permeable covalent kinase probe, reacts with conserved lysine residues within the ATP-binding site of kinases.Fórmula:C25H27FN8O3SPureza:99.02%Forma y color:SolidPeso molecular:538.6CDK9-IN-19
CAS:CDK9-IN-19: Potent CDK9 inhibitor, anti-cancer, moderate pharmacokinetics, low hERG impact, effective in AML research.Fórmula:C26H22F2N4O5Forma y color:SolidPeso molecular:508.47Mevociclib
CAS:Mevociclib (SY-1365) is a highly selective covalent inhibitor of CDK7. SY-1365 possesses therapeutic potential in both hematological and solid tumors.Fórmula:C31H35ClN8O2Pureza:98.02% - 98.02%Forma y color:SolidPeso molecular:587.11CDK7-IN-14
CAS:CDK7-IN-14 (compound 3) is a pyrimidine-derived CDK7 inhibitor applicable for studying cancers associated with transcriptional dysregulation.Fórmula:C22H24F3N6OPPureza:99.24% - 99.48%Forma y color:SolidPeso molecular:476.43SZ-015268
CAS:SZ-015268: CDK7 inhibitor, IC50=23.56 nM; hinders HCC70, OVCAR-3, HCT116, HCC1806 cell growth; strong anti-tumor effect.Fórmula:C25H38N8O3Forma y color:SolidPeso molecular:498.62Riviciclib
CAS:Riviciclib, a CDK inhibitor (CDK9/T1, CDK4/D1, CDK1/B), has IC50s: 20, 63, 79 nM respectively, and fights cisplatin-resistant tumors.Fórmula:C21H20ClNO5Pureza:98%Forma y color:SolidPeso molecular:401.84ML 315 hydrochloride
CAS:ML 315, a selective dual inhibitor targeting CDK (Cyclin-Dependent Kinase) and DYRK (Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase) with IC50 values of 68 nM and 282 nM, respectively, is utilized in research pertaining to cancer and neurological diseases [1].
Fórmula:C18H14Cl3N3O2Forma y color:SolidPeso molecular:410.682CDK9-IN-2
CAS:CDK9-IN-2, a CDK9 inhibitor from patent WO/2012131594A1, IC50: 5 nM in A2058, 7 nM in H929 at 72hr.Fórmula:C23H25ClFN5Pureza:99%Forma y color:SolidPeso molecular:425.93Ref: TM-T14918
1mg84,00€5mg177,00€10mg266,00€25mg460,00€50mg668,00€100mg945,00€1mL*10mM (DMSO)195,00€CDK7-IN-22
CAS:CDK7-IN-22 (compound 101) is a selective CDK7 inhibitor that exhibits antitumor activity, demonstrating specificity for CDK7 [1].Fórmula:C22H25F3N6Pureza:98%Forma y color:SolidPeso molecular:430.47HQ005
CAS:HQ005, a potent CCNK degrader, exhibits an impressive DC50 value of 0.041 µM and functions as a molecular-glue degrader.Fórmula:C15H15N5O2S2Forma y color:SolidPeso molecular:361.44Inixaciclib
CAS:Inixaciclib is a potent CDK inhibitor, can be used to research anticancer.Fórmula:C26H30F2N6OForma y color:SolidPeso molecular:480.55NU6300
CAS:NU6300 is a covalent CDK2 inhibitor exhibiting irreversible and ATP-competitive properties and also functions as a GSDMD (Gasdermin D) inhibitor.Fórmula:C20H23N5O3SPureza:96.08%Forma y color:SolidPeso molecular:413.49CDK7-IN-25
CAS:CDK7-IN-25 (CY-16-1) is a potent CDK7 inhibitor with an IC50 value of less than 1nM, utilized in cancer research [1].Fórmula:C33H32N6O3Pureza:98%Forma y color:SolidPeso molecular:560.65IIIM-290
CAS:IIIM-290 is an oral CDK inhibitor (IC50s: 90 and 94 nM for CDK2/A and CDK9/T1).Fórmula:C23H21Cl2NO5Pureza:98%Forma y color:SolidPeso molecular:462.32Cdc7-IN-7
CAS:Cdc7-IN-7 is a potent inhibitor of Cdc7 kinase.
Fórmula:C21H22N4O5Pureza:98.78%Forma y color:SolidPeso molecular:410.42CDK9-IN-29
CAS:CDK9-IN-29 (compound Z11) is a potent inhibitor of CDK9, exhibiting high kinase selectivity and an IC50 value of 3.20 nM.Fórmula:C29H33F2N5O4Pureza:98%Forma y color:SolidPeso molecular:553.6SHP2/CDK4-IN-1
CAS:SHP2/CDK4-IN-1: dual inhibitor, oral, potent (IC50: SHP2 4.3 nM, CDK4 18.2 nM), hinders TNBC growth, strong antitumor effects in mice.Fórmula:C33H35ClF2N10OSForma y color:SolidPeso molecular:693.21DCB-3503
CAS:DCB-3503, a tylophorine analog, may fight cancer and aid immunosuppression by hindering protein synthesis and modulating HSC70 ATPase function.Fórmula:C24H27NO5Forma y color:SolidPeso molecular:409.47KM05382
CAS:KM05382 inhibits CDK9 and the transcription of GAPDH.Fórmula:C20H19ClN2O3S2Forma y color:SolidPeso molecular:434.96CDK9-IN-23
CAS:CDK9-IN-23 (Example 4) is a potent inhibitor of CDK9, exhibiting an IC50 value of less than 20 nM [1].Fórmula:C22H25ClN4O3Pureza:98%Forma y color:SolidPeso molecular:428.91(2S,3R)-Voruciclib
CAS:(2S,3R)-Voruciclib is the (2S,3R)-enantiomer of Voruciclib. It is an orally active CDK inhibitor.Fórmula:C22H19ClF3NO5Pureza:98%Forma y color:SolidPeso molecular:469.84CCT-251921
CAS:CCT-251921 is a potent, selective, and orally bioavailable CDK8 inhibitor (IC50: 2.3 nM).Fórmula:C21H23ClN6OPureza:99.07%Forma y color:SolidPeso molecular:410.9Ref: TM-T14901
1mg90,00€5mg210,00€10mg308,00€25mg520,00€50mg745,00€100mg1.018,00€1mL*10mM (DMSO)192,00€AZD4573
CAS:AZD4573 is an effective and selective CDK9 inhibitor (IC50: <4 nM). It enables transient target engagement for the treatment of hematologic malignancies.Fórmula:C22H28ClN5O2Pureza:99% - 99.51%Forma y color:SolidPeso molecular:429.94XY028-140
CAS:XY028-140 is a selective CDK4/6 inhibitor and degrader, acting via PROTAC with ligands for Cereblon and CDK in cancer cells.Fórmula:C39H40N10O7Pureza:98.59%Forma y color:SolidPeso molecular:760.8Debio-0123
CAS:Debio-0123: potent, specific oral WEE1 inhibitor; IC50 in low nanomolar; boosts DNA damage & Carboplatin's anti-cancer effects.Fórmula:C26H28Cl2N6OPureza:99.93%Forma y color:SolidPeso molecular:511.45(R)-Simurosertib
CAS:(R)-Simurosertib ((R)-TAK-931) is an inhibitor of the ATP-competitive cell division cycle 7 (CDC7) kinase.Fórmula:C17H19N5OSPureza:99.89%Forma y color:SolidPeso molecular:341.43Cdk1/2 Inhibitor III
CAS:Cdk1/2 Inhibitor III is a selective Cdk1/2 inhibitor with an IC50 value of 2.1 μM against CDK1/cyclin B.Fórmula:C15H13F2N7O2S2Pureza:99.92%Forma y color:SolidPeso molecular:425.44CF53
CAS:CF53: potent, selective oral BET inhibitor; Ki <1 nM, Kd 2.2 nM, IC50 2 nM for BRD4 BD1; high affinity for BRD2/3/4/BRDT; effective anti-tumor agent.Fórmula:C24H25N7O2Pureza:99.72%Forma y color:SolidPeso molecular:443.5Ref: TM-T10773
1mg92,00€5mg200,00€10mg299,00€25mg484,00€50mg658,00€100mg892,00€1mL*10mM (DMSO)215,00€CDK2-IN-18
CAS:CDK2-IN-18 (compound 8q) serves as a powerful inhibitor of CDK 2/E and CDK 4/D1, showing IC50 values of 8 nM and 46 nM, respectively. It effectively inhibits tumor cell proliferation [1].Fórmula:C21H23N7O2SForma y color:SolidPeso molecular:437.52CDK2 degrader 6
CAS:CDK2 degrader6 (compound 6) is an orally active CDK2 degrader with a DC50 of 46.5 nM, and is applicable in breast cancer research.Fórmula:C23H22F5N5O3Forma y color:SolidPeso molecular:511.44INX-315
CAS:INX-315 is an orally active, selective CDK2 inhibitor that induces cell cycle arrest and senescence in solid tumours, suppresses E2F target gene expression.Fórmula:C19H21N7O3SPureza:99.88%Forma y color:SolidPeso molecular:427.48Tizolemide
CAS:Tizolemide, a sulfonamide diuretic compound with alkaline properties, is cleared through the tubular transport system. It induces changes in the passive transport components across the basolateral membrane of isolated frog skin.Fórmula:C11H14ClN3O3S2Forma y color:SolidPeso molecular:335.83CDDD11-8
CAS:CDDD11-8 is an orally administered, highly potent and selective CDK9 and FLT3-ITD inhibitor, with K i values of 8 nM and 13 nM, respectively. It effectively reduces the proliferation of leukemia cell lines, showing particular efficacy against those with the FLT3-ITD mutation [1] [2].Fórmula:C24H26N6Forma y color:SolidPeso molecular:398.50Haspin-IN-1
Haspin-IN-1 blocks haspin (IC50: 119 nM) and inhibits CLK1, DYRK1A, CDK9 with potential as an anticancer drug.Fórmula:C12H8N4O2SForma y color:SolidPeso molecular:272.28CDK1-IN-4
CDK1-IN-4 inhibits CDK1 (IC50: 44.52 nM), CDK2/CDK5 less potently, impacts cell cycle, used in cancer studies.Fórmula:C26H24ClN5SForma y color:SolidPeso molecular:474.02CDK12/13 ligand 1
CAS:ALK-IN-29 (compound 4c) exhibits notable inhibitory activity against tyrosine kinases such as ALK, CDK2/CyclinE1, and FAK, with the strongest inhibition observed against ALK kinase, showing a 40.63% inhibition rate at a concentration of 10 μM. ALK-IN-29 is useful for cancer research.Fórmula:C26H26BrN5OForma y color:SolidPeso molecular:504.42CDK2-IN-31
CAS:CDK2-IN-31 (compound I-125A) is an inhibitor of CDK2 and is utilized in cancer research.Fórmula:C37H52N6O5Forma y color:SolidPeso molecular:660.85SGC-CLK-1
CAS:SGC-CLK-1 is a potent and selective inhibitor of Cdc2-like kinases CLK1, CLK2, and CLK4. It effectively inhibits the growth of melanoma and glioblastoma cells.Fórmula:C19H15F3N6O2Forma y color:SolidPeso molecular:416.36CDK8-IN-5
CAS:CDK8-IN-5: potent CDK8 inhibitor, IC50=72 nM, boosts IL-10 by 43%, may aid inflammatory bowel disease research.Fórmula:C26H22N2O4Forma y color:SolidPeso molecular:426.46PROTAC CDK12/13 Degrader-1
PROTAC CDK12/13 Degrader-1 (7f) selectively degrades CDK12/13 at nanomolar potency, targeting breast cancer.Forma y color:SolidCDK8-IN-11 hydrochloride
CDK8-IN-11 HCl: potent, selective CDK8 inhibitor (IC50: 46 nM), blocks WNT/β-catenin pathway, used in colon cancer research.Fórmula:C19H16ClF3N4O2Forma y color:SolidPeso molecular:424.8CDK9-IN-34
CAS:CDK9-IN-34 (Compound 1b) is an inhibitor of CDK9 with an IC50 of 0.25 μM. It exhibits cytotoxicity against cancer cell lines HCT116, MCF7, and K652, with IC50 values of 1.43 μM, 3.01 μM, and 50.27 μM, respectively. Additionally, CDK9-IN-34 demonstrates antiviral activity against coronavirus 229E with an IC50 of 145.92 μM.Fórmula:C18H20N4Forma y color:SolidPeso molecular:292.38RGB-286638
CAS:RGB-286638 inhibits multiple CDKs and GSK-3β, TAK1, Jak2, MEK1 with IC50s as low as 1-54 nM.Fórmula:C29H37Cl2N7O4Forma y color:SolidPeso molecular:618.55CDK8-IN-11
CAS:CDK8-IN-11 is a CDK8 inhibitor that demonstrates anti-proliferative activity against colon cancer cell lines and inhibits the activation of WNT/β-catenin.Fórmula:C19H15F3N4O2Pureza:99.74%Forma y color:SolidPeso molecular:388.34Ref: TM-T61742
1mg54,00€5mg114,00€10mg178,00€25mg409,00€50mg708,00€100mg982,00€1mL*10mM (DMSO)126,00€Cdc7-IN-10
CAS:Cdc7-IN-10 is a potent inhibitor of Cdc7 (IC50 ≤ 1 nM) and can be used in studies of proliferative diseases.Fórmula:C20H22F2N4O2SForma y color:SolidPeso molecular:420.48Haspin-IN-2
CAS:Haspin-IN-2 is a potent haspin inhibitor (IC50: 50 nM) and also inhibits CLK1 (IC50: 445 nM) and DYRK1A (IC50: 917 nM).Fórmula:C12H8N4O3Forma y color:SolidPeso molecular:256.22Cdc7-IN-8
CAS:Cdc7-IN-8, inhibits Cdc7 kinase, key in DNA replication, and is promising for cancer research. (WO2021032170A1)Fórmula:C19H21N5O2Forma y color:SolidPeso molecular:351.40CDK7-IN-17
CAS:CDK7-IN-17 (compound 11) is a pyrimidine-derived CDK7 inhibitor for studying transcription-disrupted cancers.Fórmula:C24H26F3N6OPPureza:99.60%Forma y color:SolidPeso molecular:502.47CDK7/12-IN-1
CAS:CDK7/12-IN-1 is a selective CDK7 (IC50: 3 nM) and CDK12 (IC50: 277 nM) inhibitor, effective against tumor growth.Fórmula:C25H34N8OForma y color:SolidPeso molecular:462.59DS96432529
DS96432529 is a potent and orally active bone anabolic agent through CDK8 inhibition.Fórmula:C18H26N4O3SForma y color:SoildPeso molecular:378.49Cdc7-IN-11
CAS:Cdc7-IN-11 is a potent inhibitor of Cdc7 (IC50 ≤ 1 nM) and can be used in the study of proliferative diseases.Fórmula:C20H22F2N4O2SForma y color:SolidPeso molecular:420.48CLK1/4-IN-1
CLK1/4-IN-1 inhibits Clk1/4 (IC50: 9.7/6.6 nM), curbing T24 cell growth (GI50: 1.1 μM). Potential cancer research tool.Fórmula:C18H14ClNO4SForma y color:SolidPeso molecular:375.83CDK9-IN-13
CDK9-IN-13 is a potent and selective CDK inhibitor (IC50<3 nM). CDK9-IN-13 has a very short half-life in rodents.Fórmula:C27H35N5O2Forma y color:SolidPeso molecular:461.6CDK1-IN-3
CDK1-IN-3 is a selective inhibitor targeting CDK1 (36.8 nM), CDK2 (305.17 nM), CDK5 (369.37 nM); used in cancer research.Fórmula:C28H25ClF3N5O2Forma y color:SolidPeso molecular:555.98CDK/HDAC-IN-1
CDK/HDAC-IN-1 inhibits CDK2/4/6 & HDAC6 with IC50s: 60.9, 276, 27.2, and 128.6 nM respectively.Fórmula:C20H18N4O4Forma y color:SolidPeso molecular:378.38CDK7-IN-33
CAS:CDK7-IN-33 (Compound 148) is a CDK7 inhibitor with a Ki value of 21.75 nM. It suppresses the proliferation of A549 cells expressing CDK7WT, with a pIC50 of 7.37.Fórmula:C29H36N6O4SForma y color:SolidPeso molecular:564.699CDK8-IN-9
CDK8-IN-9, potent CDK8 inhibitor (IC50: 48.6 nM), curbs tumor growth, useful for colorectal cancer research.Forma y color:SolidYL-1-9
CAS:YL-1-9 is an inhibitor that prevents the degradation of p53 by MDM2 through tight binding to the crucial hydrophobic pocket of MDM2. It can induce cell cycle arrest and apoptosis in breast cancer cells [1].Fórmula:C22H23F3N2O3Forma y color:SolidPeso molecular:420.425CLK1/2-IN-1
CAS:CLK1/2-IN-1 is a CLK1 and CLK2 inhibitor and it also inhibits SRPK1 and SRPK2.Fórmula:C21H20F3N7OPureza:98%Forma y color:SolidPeso molecular:443.42GSK3-IN-10
CAS:GSK3-IN-10 (Compound 4) is a multi-target inhibitor primarily affecting GSK3α and GSK3β with IC50 values of 1.0 nM and 2.0 nM, respectively. It inhibits the activation of β-catenin, enhances neuronal survival, and provides protective effects against endoplasmic reticulum stress.Fórmula:C17H18F2N4O3Forma y color:SolidPeso molecular:364.347CDK4/6-IN-13
CAS:Compounds 10B and 10C: potent cdk4/6 inhibitors with low nM activity, great antiproliferative effects, excellent metabolism, and good pharmacokinetics.Fórmula:C25H29N7OForma y color:SolidPeso molecular:443.54Anticancer agent 29
Compound E/Z-6f, anticancer, IC50: CDK2 (0.054 μM), CDK1 (0.127 μM), CDK4 (0.129 μM), CDK6 (0.396 μM).Fórmula:C22H15ClFNOForma y color:SolidPeso molecular:363.81
